Shots:
The P-III (SKYSCRAPER-01) study evaluating tiragolumab + Tecentriq vs Tecentriq alone in a ratio (1:1) in 534 patients with PD-L1-high LA or metastatic NSCLC
The study failed to meet its co-primary EPs of PFS & the other co-primary EPs of OS were immature, numerical improvement was identified in both co-primary EPs. The results demonstrated that the therapy was well-tolerated and no new safety signals were reported
The program continues to advance the therapy for multiple clinical trials & expand into earlier stages of the disease. The company focuses to develop novel therapeutic options for malignancies that are advanced and difficult to treat in patients with a high unmet medical needs
Ref: Roche | Image: Roche
